Cas no 26116-56-3 (Erythromycylamine)
Erythromycylamine is a semisynthetic derivative of erythromycin, belonging to the macrolide class of antibiotics. It exhibits broad-spectrum activity against Gram-positive bacteria and some Gram-negative organisms, making it valuable in treating respiratory, skin, and soft tissue infections. The compound's modified structure enhances stability against acid degradation, improving oral bioavailability compared to its parent molecule. Erythromycylamine retains the ribosomal binding mechanism of macrolides, inhibiting bacterial protein synthesis. Its pharmacokinetic profile includes favorable tissue penetration and prolonged half-life, allowing for less frequent dosing. The derivative also demonstrates reduced gastrointestinal side effects, a common limitation of earlier macrolides. These properties position erythromycylamine as a clinically relevant therapeutic option.
Erythromycylamine structure
Product Name:Erythromycylamine
CAS No:26116-56-3
MF:C37H70N2O12
MW:734.957912921906
MDL:MFCD00872156
CID:274172
PubChem ID:83952
Update Time:2025-11-07
Erythromycylamine Chemical and Physical Properties
Names and Identifiers
-
- Erythromycin,9-amino-9-deoxo-, (9S)-
- Erythromycylamine
- (9S)-erythromycylamine
- (9S)-erythromycylamine A
- 9-((2S)-3-Hydroxy-2-phosphonylmethoxypropyl)-6-oxopurine
- 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)hypoxanthine
- 9(S)-Erythromycylamine
- 9-(S)-erythromycylamine A
- 9-[(2S)-3-Hydroxy-2-phosphonylmethoxypropyl]-6-oxopurine
- AC1L9PY9
- Phosphonic acid, ((2-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-(hyd
- Phosphonic acid, [[2-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)-
- (9S)-9-Amino-9-deoxoerythromycin
- 9-Epierythromycylamine
- Epierythromycyl-A-amine
- (9S)-erythromycyclamine
- YX9KV1OMA4
- 9-Amino-9-deoxoerythromycin
- 9-Amino-9-deoxo-erythromycin, stereoisomer
- Erythromycin, 9-amino-9-deoxo-, (9S)- (9CI)
- Erythromycin, 9-amino-9-deoxo-, stereoisomer
- AC-28327
- DTXSID00180750
- CS-15835
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-amino-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one
- LY-24410
- (9S)-9-Deoxy-9-aminoerythromycin A
- D95598
- SCHEMBL13681694
- AKOS037651084
- HY-W055872
- UNII-YX9KV1OMA4
- MFCD00872156
- RAN-2-YL]OXY}-14-ETHYL-7,12,13-TRIHYDROXY-4-{[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYLTETRAHYDRO-2H-PYRAN-2-YL]OXY
- EC 406-790-7
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-amino-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one (non-preferred name)
- BRN 4241492
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-amino-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
- Q27144058
- CHEBI:73708
- ERN
- CHEMBL290242
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-AMINO-6-{[(2S,3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYLTETRAHYDRO-2H-PY RAN-2-YL]OXY}-14-ETHYL-7,12,13-TRIHYDROXY-4-{[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYLTETRAHYDRO-2H-PYRAN-2-YL]OXY }-3,5,7,9,11,13-HEXAMETHYLOXACYCLOTETRADECAN-2-ONE
- J-016261
- LY-024410
- 26116-56-3
- CS-0047729
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-10-AMINO-6-{[(2S,3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYLTETRAHYDRO-2H-PY
- }-3,5,7,9,11,13-HEXAMETHYLOXACYCLOTETRADECAN-2-ONE
- EX-A5468
- (9S)-9-amino-9-deoxyerythromycin
- Erythromycin, 9-amino-9-deoxo-, (9S)-
- BDBM50417963
- BRL-42852ER
- XCLJRCAJSCMIND-JCTYMORFSA-N
-
- MDL： MFCD00872156
- Inchi： 1S/C37H70N2O12/c1-14-25-37(10,45)30(41)20(4)27(38)18(2)16-35(8,44)32(51-34-28(40)24(39(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-32,34,40-42,44-45H,14-17,38H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,27+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
- InChI Key： XCLJRCAJSCMIND-JCTYMORFSA-N
- SMILES： O([C@H]1[C@@H]([C@H](C[C@@H](C)O1)N(C)C)O)[C@@H]1[C@@H](C)[C@@H]([C@@H](C)C(=O)O[C@H](CC)[C@](C)([C@@H]([C@@H](C)[C@H]([C@H](C)C[C@@]1(C)O)N)O)O)O[C@H]1C[C@](C)([C@H]([C@H](C)O1)O)OC
- BRN： 4241492
Computed Properties
- Exact Mass: 734.49300
- Monoisotopic Mass: 734.49287567g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 6
- Hydrogen Bond Acceptor Count: 14
- Heavy Atom Count: 51
- Rotatable Bond Count: 7
- Complexity: 1140
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 19
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.5
- Topological Polar Surface Area: 203
Experimental Properties
- Melting Point: 123-127°C
- PSA: 202.86000
- LogP: 2.24410
Erythromycylamine Security Information
- Hazard Category Code： 41-50/53
- Safety Instruction： 26-39-60-61
-
Hazardous Material Identification：
- Risk Phrases：R41; R50/53
Erythromycylamine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-ND232-250mg |
Erythromycylamine |
26116-56-3 | 95% | 250mg |
1870CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-ND232-1g |
Erythromycylamine |
26116-56-3 | 95% | 1g |
1897.0CNY | 2021-07-15 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-ND232-100mg |
Erythromycylamine |
26116-56-3 | 95% | 100mg |
873CNY | 2021-05-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci75140-1mg |
Erythromycylamine |
26116-56-3 | 98% | 1mg |
￥2229.00 | 2022-04-26 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci75140-5mg |
Erythromycylamine |
26116-56-3 | 98% | 5mg |
￥8438.00 | 2022-04-26 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci75140-500ug |
Erythromycylamine |
26116-56-3 | 98% | 500ug |
￥1396.00 | 2022-04-26 | |
| TRC | E653400-1mg |
Erythromycylamine |
26116-56-3 | 1mg |
$ 155.00 | 2023-09-07 | ||
| TRC | E653400-2mg |
Erythromycylamine |
26116-56-3 | 2mg |
$283.00 | 2023-05-18 | ||
| TRC | E653400-5mg |
Erythromycylamine |
26116-56-3 | 5mg |
$ 685.00 | 2023-09-07 | ||
| TRC | E653400-10mg |
Erythromycylamine |
26116-56-3 | 10mg |
$1211.00 | 2023-05-18 |
Erythromycylamine Suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier
(CAS:26116-56-3)(9S)-紅霉胺
Order Number:LE25860786
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:50
Price ($):discuss personally
Email:[email protected]
Erythromycylamine Related Literature
-
1. NMR spectroscopic and X-ray crystallographic studies on the structure, stereochemistry and conformation of a series of 9,11-cyclic aminals of (9S)-9-N-methylerythromycylamine AJ. Sydney Davies,Jeremy R. Everett,Ian K. Hatton,Eric Hunt,John W. Tyler,Iskander I. Zomaya,Alexandra M. Z. Slawin,David J. Williams J. Chem. Soc. Perkin Trans. 2 1991 201
-
2. Substituent effects on the pK a values and rates of hydrolysis of arylmethylene-erythromycylaminesAnthony F. Cockerill,M. F. Ellis,David M. Rackham,Eric Wildsmith a values and rates of hydrolysis of arylmethylene-erythromycylamines. Anthony F. Cockerill M. F. Ellis David M. Rackham Eric Wildsmith J. Chem. Soc. Perkin Trans. 2 1973 173
-
3. The conformational analysis of three derivatives of erythromycin A: (9S)-9-hydroxy-9-deoxoerythromycin A, (9S)-9,11-O-isopropylidene-9-deoxoerythromycin A, and (9S)-erythromycylamine A by nuclear magnetic resonance spectroscopy and molecular modellingJeremy R. Everett,John W. Tyler J. Chem. Soc. Perkin Trans. 2 1988 325
-
4. The conformational analysis of derivatives of erythromycin A. X-Ray crystallographic and nuclear magnetic resonance spectroscopic studies of (E)-11-O-(2-dimethylaminoethoxy)methyl-9-deoxo-9-methoxyiminoerythromycin AJeremy R. Everett,Ian K. Hatton,Eric Hunt,John W. Tyler,David J. Williams J. Chem. Soc. Perkin Trans. 2 1989 1719
-
5. The chemistry of erythromycin. Reactions of erythromycin A imine and its 6-methyl ether with aldehydes and hydrazinesJ. Sydney Davies,Eric Hunt,Iskander I. Zomaya J. Chem. Soc. Perkin Trans. 1 1990 1409
Additional information on Erythromycylamine
Market Research and Analysis of Erythromycylamine (CAS No. 26116-56-3) in the Chemical-Biomedical Field
Erythromycylamine, identified by the CAS number 26116-56-3, is a significant compound in the chemical-biomedical industry, particularly in the realms of drug development and research. This compound has garnered attention due to its potential applications in therapeutic interventions and its role as an intermediate in the synthesis of complex biomolecules.
The global market for Erythromycylamine is driven by increasing demand from pharmaceutical companies engaged in antibiotic research and development. The compound's unique chemical properties make it a valuable asset in the creation of novel drug formulations, particularly those targeting bacterial infections. Recent advancements in synthetic chemistry have further enhanced its accessibility and applicability in large-scale production.
Market analysis indicates a growing interest in Erythromycylamine among academic institutions and private research organizations. Its role as a key intermediate in the synthesis of macrolide antibiotics has positioned it as a critical component in the fight against antibiotic resistance. The compound's versatility is also evident in its use across diverse therapeutic areas, including oncology and infectious diseases.
From a supply chain perspective, the production of Erythromycylamine is concentrated among a few specialized manufacturers, primarily located in Asia. These suppliers have established robust quality control systems to meet the stringent requirements of the pharmaceutical industry. However, rising raw material costs and regulatory scrutiny pose challenges to maintaining competitive pricing.
Recent studies have highlighted the potential for Erythromycylamine to serve as a platform for developing next-generation therapeutics. Collaborative efforts between academia and industry are expected to accelerate its integration into clinical pipelines, further bolstering its market presence.
In conclusion, Erythromycylamine (CAS No. 26116-56-3) holds immense promise in advancing chemical-biomedical research and drug development. Its strategic importance is underscored by its role as a versatile building block in therapeutic innovation, making it a focal point for future market growth and investment.
26116-56-3 (Erythromycylamine) Related Products
- 76801-85-9(Azathramycin)
- 217500-96-4(Tulathromycin A)
- 119904-03-9(Erythromycin,9-deoxo-9-(propylamino)-, (9S)-)
- 13368-00-8(Erythromycin,9-amino-9-deoxo- (9CI))
- 145435-72-9(Gamithromycin)
- 83905-01-5(Azithromycin)
- 117772-70-0(Azithromycin hydrate)
- 121470-24-4(Azithromycin monohydrate)
- 122463-26-7(CP 63956 (9CI))
- 146763-21-5(1-Oxa-5-azacyclotetradecan-14-one,12-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,9-dihydroxy-3,7,9,11,13-pentamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-,[2R-(2R*,3S*,7R*,9R*,10R*,11S*,12S*,13R*)]- (9CI))
Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:26116-56-3)(9S)-紅霉胺
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry